Sensorion SA (PA:ALSEN) — Market Cap & Net Worth
Market Cap & Net Worth: Sensorion SA (ALSEN)
Sensorion SA (PA:ALSEN) has a market capitalization of $166.23 Million (€142.18 Million) as of May 4, 2026. Listed on the PA stock exchange, this France-based company holds position #17225 globally and #257 in its home market, demonstrating a 5.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sensorion SA's stock price €0.40 by its total outstanding shares 514632940 (514.63 Million). Analyse ALSEN operating cash flow to see how efficiently the company converts income to cash.
Sensorion SA Market Cap History: 2015 to 2026
Sensorion SA's market capitalization history from 2015 to 2026. Data shows change from $5.25 Billion to $243.07 Million (-27.82% CAGR).
Sensorion SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sensorion SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
57.52x
Sensorion SA's market cap is 57.52 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.25 Billion | $157.51K | -$4.27 Million | 33308.42x | N/A |
| 2016 | $2.89 Billion | $17.50K | -$7.41 Million | 165370.55x | N/A |
| 2017 | $2.23 Billion | $1.93 Million | -$9.69 Million | 1150.79x | N/A |
| 2018 | $605.27 Million | $2.23 Million | -$12.35 Million | 271.37x | N/A |
| 2019 | $508.40 Million | $2.46 Million | -$12.10 Million | 206.95x | N/A |
| 2020 | $902.49 Million | $2.35 Million | -$8.98 Million | 383.70x | N/A |
| 2021 | $1.16 Billion | $4.26 Million | -$15.14 Million | 271.78x | N/A |
| 2022 | $222.61 Million | $4.93 Million | -$23.21 Million | 45.12x | N/A |
| 2023 | $258.71 Million | $5.70 Million | -$22.06 Million | 45.40x | N/A |
| 2024 | $382.66 Million | $6.65 Million | -$25.97 Million | 57.52x | N/A |
Competitor Companies of ALSEN by Market Capitalization
Companies near Sensorion SA in the global market cap rankings as of May 4, 2026.
Key companies related to Sensorion SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Sensorion SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Sensorion SA's market cap moved from $5.25 Billion to $ 243.07 Million, with a yearly change of -27.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €243.07 Million | +19.88% |
| 2025 | €202.76 Million | -47.01% |
| 2024 | €382.66 Million | +47.91% |
| 2023 | €258.71 Million | +16.22% |
| 2022 | €222.61 Million | -80.79% |
| 2021 | €1.16 Billion | +28.40% |
| 2020 | €902.49 Million | +77.51% |
| 2019 | €508.40 Million | -16.00% |
| 2018 | €605.27 Million | -72.81% |
| 2017 | €2.23 Billion | -23.08% |
| 2016 | €2.89 Billion | -44.84% |
| 2015 | €5.25 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Sensorion SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $166.23 Million USD |
| MoneyControl | $166.23 Million USD |
| MarketWatch | $166.23 Million USD |
| marketcap.company | $166.23 Million USD |
| Reuters | $166.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sensorion SA
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, whi… Read more